Entries |
Document | Title | Date |
20080207769 | Method for treating benign prostatic hyperplasia - The use of 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol, or a pharmaceutically acceptable salt or ester thereof, for the manufacture of a medicament for the prevention and/or treatment of benign prostatic hyperplasia (BPH) and associated symptoms. | 08-28-2008 |
20080255245 | Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxystilbenes and Novel Stilbene Derivatives and Analogues - The present invention provides novel diphenyl ethene compounds and pharmaceutically-acceptable salts thereof. Also provided are methods for making the compounds of the invention as well as methods for the use thereof in the treatment of immune, inflammatory, and auto-immune diseases. | 10-16-2008 |
20080306166 | Compositions and Methods For Treatment of Disorders of Protein Aggregation - The invention provides compositions, methods and uses comprising a scyllo-inositol compound that provide beneficial effects in the treatment of a disorder and/or disease including a disorder in protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence. | 12-11-2008 |
20090062403 | Compositions and Methods for Treatment of Disorders of Protein Aggregation - The invention provides compositions, methods and uses comprising a scyllo-inositol compound that provide beneficial effects in the treatment of a disorder and/or disease including a disorder in protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence. | 03-05-2009 |
20090118379 | PROCESS FOR THE MANUFACTURE OF A COMPOSITION CONTAINING AT LEAST ONE XANTHOPHYLL - The present invention relates to a process for the manufacture of a composition containing at least one xantophyll selected from the group consisting of lutein and zeaxanthin, said process comprising the steps of: providing an extract of Marigold flower containing the xantophyll(s) in esterified form; saponifying the Marigold flower extract and isolating the xantophyll(s). The process according to the invention is characterized in that the step of saponifying the Marigold flower extract is carried out in the presence of a quaternary ammonium base. | 05-07-2009 |
20090143483 | Therapeutic or preventive drug for osteoporosis comprising isotaxiresinol derived from taxus yunnanensis - The object of the present invention is to provide a drug effective in treating or preventing osteoporosis. The present invention discloses a therapeutic or preventive drug for osteoporosis having a compound shown in the formula (1) | 06-04-2009 |
20090143484 | USE OF GARLIC OIL TO INCREASE BIOAVAILABILITY OF COENZYME Q-10 - The invention describes compositions that include a sulfide containing molecule, such a garlic oil, and a coenzyme Q molecule. The sulfide containing molecule solvates the coenzyme Q molecule, thus enhancing the bioavailability of the coenzyme Q molecule in a subject in need thereof, relative to administration of coenzyme Q devoid of the presence of a sulfide containing molecule. | 06-04-2009 |
20090156688 | SUPPRESSANT OF TOXICITY INDUCED BY CANCER CHEMOTHERAPEUTIC AGENT AND COMPOSITION OF CANCER CHEMOTHERAPEUTIC AGENT CONTAINING THE SAME - Disclosed are a suppressant of toxicity such as hepatotoxicity and nephrotoxicity, induced by cancer chemotherapeutic agent, and a composition of cancer chemotherapeutic agent containing the suppressant. The suppressant of toxicity induced by a cancer chemotherapeutic agent contains xanthorrhizol as an active ingredient. Xanthorrhizol shows an excellent ability in suppressing ill effects generated by dosage of cancer chemotherapeutic agent, such as hepatotoxicity and nephrotoxicity. | 06-18-2009 |
20090186950 | 13,13-Dimethyl-des-C,D Analogs of 1Alpha,25-Dihydroxy-19-Nor-Vitamin D3 Compounds and Topical Composition Dosage Forms and Methods of Treating Skin Conditions Thereof - 13,13-Dimethyl-des-C,D analogs of 1α,25-dihydroxy-19-nor-vitamin D | 07-23-2009 |
20090247646 | USE OF RESVERATROL AND DERIVATIVES THEREOF FOR PROMOTING THE WELLNESS STATE IN MAMMALS - The invention relates to the use of resveratrol, a derivative, metabolite or analogue thereof for promoting the wellness state of a mammal or for changing gene expression profiles in older adult mammals towards conformity with expression profiles found in younger adult mammals as well as to their use for the manufacture of corresponding nutraceutical compositions. | 10-01-2009 |
20090281197 | Acetic Acid/Thymol Compositions and Their Use in the Treatment of Onychomycosis - A composition comprising from about 1 weight part to about 10 weight parts a saturated carboxylic acid having from 2 to about 20 carbon atoms; from about 0.1 weight parts to about 10 weight parts an antifungal compound; and from about 80 weight parts to about 99 weight parts skin-penetrating gel; wherein the saturated carboxylic acid, the antifungal compound, and the skin-penetrating gel together comprise 100 weight parts. In a particular example of the composition, the saturated carboxylic acid having from 2 to about 20 carbon atoms is acetic acid; and the antifungal compound is thymol. A method of treating onychomycosis in a patient, comprising applying the composition. The method provides a safe, effective treatment of onychomycosis. | 11-12-2009 |
20090292028 | Menthol-containing formulation - It is known that L-menthol controls smooth muscle contraction. In order to use L-menthol in practice as a digestive tract contraction inhibiting agent in digestive tract endoscopy, it is required to devise means of giving a formulation in which an L-menthol-containing formulation remains stable and transparent or little cloudy over a long time after the production and which shows little foaming at the administration. In the present invention, an antifoaming agent is further added to a formulation for inhibiting smooth muscle contraction or a peristaltic contraction in a digestive tract containing a L-menthol emulsion having an average particle size of less than 100 nm. | 11-26-2009 |
20090306221 | Use for Cannabinoid - The present invention relates to the use of one or more cannabinoids in the manufacture of medicaments for use in 0 the treatment of diseases and conditions benefiting from inverse agonism of the CB | 12-10-2009 |
20090312438 | Compositions and Methods for Attenuating the Formation of A2E in the Retinal Pigment Epithelium - A method of decreasing the content of 2-(2,6-dimethyl-8-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1E,3E,5E,7E-octatetraenyl)-1-(2-hydroxyethyl)-4-(4-methyl-6-(2,6,6-trimethyl-1cyclohexen-1-yl)-1E,3E,5E-hexatrienyl-pyridinium (A2E) and its isomers in a subject by administering a therapeutically effective amount of a macular carotenoid formulation. | 12-17-2009 |
20100056644 | PHARMACEUTICAL COMPOSITIONS CONTAINING ANHYDROUS CALCIPOTRIENE - A stable pharmaceutical composition in a semisolid dosage form comprising a therapeutic effective amount of solubilized calcipotriene in an anhydrous form is disclosed. | 03-04-2010 |
20100063163 | Extract Solution Comprising a B-Cryptoxanthin Component and Food and Drink Soaps - There are provided an extract solution to be added to food and drink containing a β-cryptoxanthin component consisting of an extract containing a β-cryptoxanthin component dissolved or dispersed in fat or oil or in a solution comprising an emulsifier and an extract solution to be added to soaps or cosmetics containing a β-cryptoxanthin component consisting of an extract containing a β-cryptoxanthin component dissolved or dispersed in fat or oil or in a solution comprising an emulsifier. There are also provided food and drink or soaps or cosmetics added with such extract solution containing a β-cryptoxanthin component. An extract containing a β-cryptoxanthin component derived from persimmon peel is preferable. | 03-11-2010 |
20100076091 | COMPOSITION AND METHOD FOR SUPPRESSING LIPOOXIDATION OF ERYTHROCYTE - The present invention relates to a composition for suppressing lipoperoxidation of erythrocytes, which comprises xanthophyll or an ester thereof as an active ingredient, a composition for preventing or treating dementia, and a method for diagnosing dementia, which comprises measuring the concentration of xanthophyll or an ester thereof in mammalian erythrocytes. | 03-25-2010 |
20100144891 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS - The present invention relates to methods for modulating, disrupting or enhancing the clearance of copper/zinc superoxide dismutase 1 (SOD1) aggregates in astrocytes or motor neurons in a subject, by administering a medicament comprising a therapeutically effective amount of a cyclohexanehexyl derivative. In another aspect, the invention provides a medicament comprising at least one cyclohexanehexyl derivative of formula III or IV useful in preventing or treating amyothropic lateral sclerosis (ALS), improving motor neuron function and slowing the degeneration or death of motor neurons in brain stem, spinal cord or motor cortex. These medicaments may be administered orally, intravenously, intraperitoneal, subcutaneous, intramuscular, intranasal or transdermal. | 06-10-2010 |
20100152305 | METHODS OF TREATMENT OF HYPERURICEMIA AND ASSOCIATED DISEASE STATES - The present disclosure relates to compositions and methods for reducing uric acid levels in a individual in need thereof. The present disclosure further relates to the treatment of hyperuricemia and diseases associated with high uric acid levels in mammals using scyllo-inositol. | 06-17-2010 |
20100160454 | ANTIMICROBIAL AGENTS, COMPOSITIONS AND PRODUCTS CONTAINING THE SAME, AND METHODS OF USING THE COMPOSITIONS AND PRODUCTS - Antimicrobial agents, products and compositions incorporating the agents, and methods of using the compositions and products are provided. The antimicrobial agents comprise 1,2-cyclohexanedimethanol, 1,4-cyclohexanedimethanol, 2,2,4,4-tetramethyl-1,3-cyclobutanediol, or mixtures thereof. These agents have surprisingly been found to inhibit microbial growth at a much lower concentration than other glycols with known antimicrobial activity. | 06-24-2010 |
20100160455 | VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS - Novel vitamin D analogues are useful for making pharmaceutical compositions for the prevention or treatment of bone disorders such as osteoporosis | 06-24-2010 |
20100210734 | METHOD OF USING CALCITRIOL FOR TREATING INTRAOCULAR DISEASES ASSOCIATED WITH ANGIOGENESIS - The present invention provides a method of treating pathologies resulting from neovascular growth in the eye such as those manifested as retinopathy of prematurity, diabetic retinopathy and macular degeneration. The invention comprises the administration of an effective amount of calcitriol that is administered at doses less than toxicity and results in a significant reduction in the formation of neo-vascular growth. The invention can be used to treat existing diseases or prophylactically to treat those at risk. | 08-19-2010 |
20100305214 | Use of a Monoterpene to Increase Tissue Repair - The invention relates to the use of a monoterpene to increase biological tissue repair, i.e. tissue regeneration or healing, the cosmetic use of a monoterpene to increase biological tissue repair of skin or a mucosa in an individual and the use of a monoterpene for the manufacture of a pharmaceutical composition intended to prevent or treat a biological tissue injury in an individual. | 12-02-2010 |
20100324151 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFECTION OR INFECTIOUS COLONIZATION OF THE EYELID, OCULAR SURFACE, SKIN OR EAR - The instant invention provides methods and compositions for the treatment of infection or infectious colonization of the eyelid and/or ocular surface for the treatment and prevention of ocular disorders and eyelid disorders. | 12-23-2010 |
20110009496 | RESVERATROL FORMULATIONS - Resveratrol can be used to treat or inhibit the onset of many diseases that are related to the aging process, but large doses are required. The present invention provides concentrated liquid formulations of resveratrol, typically having a resveratrol concentration of at least 10% by weight. These formulations improve patient compliance because the patient need not consume such a large volume of a resveratrol formulation. | 01-13-2011 |
20110015276 | THERAPEUTICAL USES OF INECALCITOL - The present invention thus concerns a method for treating and/or preventing rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D relevant disease comprising administering inecalcitol at doses comprised between 1 mg/day and 100 mg/day to a human patient in need thereof. | 01-20-2011 |
20110015277 | METHOD OF PRODUCING EGG YOLK BASED FUNCTIONAL FOOD PRODUCT AND PRODUCTS OBTAINABLE THEREBY - The present invention relates to the field of food products, especially food products specifically designed for providing health benefits beyond the basic function of nutrition for a subject consuming the product on a regular basis, e.g. on a daily basis. According to the present invention eggs are produced, in particular chicken eggs, that are enriched in one or more pharmacologically active nutrients. The egg yolk obtained from the aforementioned eggs can suitably be used in high amounts as a component of a functional food product having all the characteristics that are normally required for such functional food products. A preferred example of a food product in accordance with the invention is a ready to drink shot containing approximately one whole egg yolk in a volume as small as 100 ml. | 01-20-2011 |
20110021639 | Microbially stable dispersion medium for emulsions - The present invention relates to novel microbial stable emulsions advantageously utilizing dispersion media characterized by lower water activity and advantageously utilizing dispersants which exhibit high water binding capacity and which exhibit characteristics which provide for steric stabilization and charge distribution (zeta potential) in relation to the dispersed phase, and methods of using the same. | 01-27-2011 |
20110028566 | COMPOSITIONS AND PRODUCTS CONTAINING CYCLOALIPHATIC DIOL ANTIMICROBIAL AGENTS AND METHODS OF USING THE COMPOSITIONS AND PRODUCTS - Compositions comprising at least one cycloaliphatic diol antimicrobial agent and at least one other antimicrobial agent and methods of making and using these compositions are provided. The cycloaliphatic diol antimicrobial agents comprise 1,1-cyclohexanedimethanol, 1,2-cyclohexanedimethanol, 1,4-cyclohexanedimethanol, 2,2,4,4-tetramethyl-1,3-cyclobutanediol, or mixtures thereof. | 02-03-2011 |
20110028567 | SMOOTH MUSCLE CONTRACTION INHIBITORS - An emulsion comprising L-Menthol, a fat or oil and a surfactant wherein oil particles have an average diameter of 100 nm or less inhibits a content reduction attributed to, for example, evaporation of L-menthol, enhances a light transmission through liquid and is stable despite long-term storage. Thus, the emulsion can be appropriately used in the temporary inhibition of contraction of gastrointestinal tract for, for example, observation of gastrointestinal tract by an endoscope. This emulsion can be obtained by heating an oil-in-water type emulsion comprising L-menthol, a fat or oil and a surfactant at 60° C. or higher. | 02-03-2011 |
20110046237 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS - Disclosed herein are methods of treatment and prevention of diseases and disorders related to estrogen receptors comprising administering novel di-aromatic compounds to patients in need thereof. | 02-24-2011 |
20110054040 | Bicyclic Triterpenoid Iripallidal as a Novel Anti-Glioma and Anti-Neoplastic Therapy - This invention relates to a Bicyclic triterpenoid Iripallidal as a novel anti-glioma and anti neoplastic agent, having the composition [(−)(6R,10S,11S,18R,22S)-26 Hydroxy-22-α methylcyloirid-16-enal NSC 631939], wherein it binds to Ras GRP3, a phorbol ester receptor that links DAG/phorbolester signaling with Ras activation and induces phosphorylation of ER K1/2 in a Ras dependent manner, reducing proliferation of cancer cell lines to the extent of 50-70%. | 03-03-2011 |
20110065805 | XANTHOPHYLL COMPOSITION CONTAINING MACULAR PIGMENTS AND A PROCESS FOR ITS PREPARATION - A xanthophyll composition that contains macular pigments including trans-lutein and zeaxanthin isomers, namely, (R,R)-zeaxanthin and (R,S)-zeaxanthin, derived from the plant extract/oleoresin containing xanthophylls/xanthophylls esters which is safe for human consumption and useful for nutrition and health care. The composition has at least 80% by weight that is total xanthophylls, of which the ratio of trans-lutein and zeaxanthin isomers being in the range of about 4:1 to about 6:1 and the ratio of the isomers of zeaxanthin being in the range of about 80 to 20:20 to 80. | 03-17-2011 |
20110105626 | USE OF CYCLOHEXANEHEXOL DERIVATIVES FOR THE TREATMENT OF POLYGLUTAMINE DISEASES - The present invention relates to methods to modulate the assembly, folding, accumulation, rate of aggregation, oligomerization or clearance of proteins or fragments comprising PoIyQ, by using compositions comprising cyclohexanehexol derivatives. More specifically, the invention provides a medicament comprising cyclohexanehexol derivatives of formula III or formula IV, more particularly a scyllo-inositol compound, analog or derivative thereof, useful in the treatment of polyglutamine diseases, such as Huntington's disease and related neurodegenerative disorders including dentatorubral pallidoluysian atrophy, spinal and bulbar muscular atrophy and spinocerebellar ataxia type 1, 2, 3, 6, 7 and 17. | 05-05-2011 |
20110172313 | Image quality in the eye - Pharmaceutical compositions or dietary supplements are provided containing lutein, zeaxanthin, or mixtures thereof in amounts effective to improve image quality in the human eye. Methods are also provided for reducing higher order wavefront aberrations in the human eye to improve image quality by administering to a person in need of such treatment an effective amount of lutein, zeaxanthin or mixtures thereof. | 07-14-2011 |
20110201694 | Compositions and Methods for Treatment of Disorders of Protein Aggregation - The invention provides compositions, methods and uses comprising a scyllo-inositol compound that provide beneficial effects in the treatment of a disorder and/or disease including a disorder in protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence. | 08-18-2011 |
20110213039 | INFANT FORMULAS CONTAINING DOCOSAHEXAENOIC ACID AND LUTEIN - Disclosed is a method of reducing the risk or severity of retinopathy of prematurity in preterm infants. The method comprises (a) measuring skin carotenoid levels in preterm infants, preferably by Raman Spectroscopy, and then (b) administering supplemental carotenoids to those infants in need thereof, wherein the supplemental carotenoids comprise lutein, lycopene, beta-carotene, and zeaxanthin. The supplemental carotenoids may be provided by an infant formula comprising, on a ready-to-feed basis, from about 100 to about 2000 mcg/liter of total carotenoids, wherein the total carotenoids include at least about 50 mcg/liter of lutein. The formulas may further comprise docosahexaenoic acid. | 09-01-2011 |
20110251290 | TREATMENT OF HEPATIC ENCEPHALOPATHY AND LIVER CIRRHOSIS - The compounds D9-tetrahydrocannabinol (THC), cannabidiol (CBD) and capsaicin are useful for prevention, treatment, or both, of hepatic encephalopathy. The compounds capsaicin, 2-arachidonoylglycerol (2-AG), HU-308 and cannabidiol are useful for prevention, treatment, or both, of liver cirrhosis. | 10-13-2011 |
20110306677 | Pressure Sensitive Adhesive Composition and Pressure Sensitive Adhesive Tape - A pressure sensitive adhesive composition comprising, as a rubber component solid at ordinary temperature, from 10% by mass or more to less than 50% by mass of polyisoprene, from more than 50% by mass to 90% by mass or less of a styrene-isoprene-styrene block copolymer and 0 to 30% by mass of polyisobutylene, and further comprising, per 100 parts by mass of the solid rubber component, 1 to 30 parts by mass of polyisobutylene liquid at ordinary temperature, 50 to 120 parts by mass of a tackifier, and 1 to 40 parts by mass of a plasticizer liquid at ordinary temperature; and a pressure sensitive adhesive tape comprising a base material and the above-described pressure sensitive adhesive composition provided on the base material. | 12-15-2011 |
20120004320 | Method for Treating Ocular Demodex - The present invention relates to a method for treating a disorder chosen from ocular | 01-05-2012 |
20120065273 | TTO-BASED WIDE SPECTRUM THERAPEUTICS, DISINFECTANTS & ANESTHETICS FOR USE IN AQUACULTURE - The invention discloses a novel wide spectrum aquaculture pharmaceutical, comprising a therapeutic, disinfective and/or anesthetize effective amount of a preparation comprising TTO in a stable water-in-oil emulsion of alkali or ammonium salts of organic fatty acid; said emulsion is also stable when converted into an oil-in-water emulsion, wherein the preparation is for the treatment of aquatic animals suffering from a disease selected from bacterial, parasitic, viral and mycotic diseases. The invention also discloses a method for treating diseases selected from bacterial, parasitic, viral and mycotic origin, in an aquatic animal suffering therefrom, which method comprises administering a therapeutic active amount of a preparation comprising TTO in a stable water-in-oil emulsion of alkali or ammonium salts of organic fatty acid; said emulsion is also stable when converted into an oil-in-water emulsion to said aquatic animal. | 03-15-2012 |
20120071562 | 2alpha-Methyl-19-Nor-(20S)-1alpha-Hydroxy-Bishomopregnacalciferol and Its Uses - This invention discloses 2α-methyl-19-nor-(20S)-vitamin D analogs, and specifically 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity. | 03-22-2012 |
20120095108 | COMPOSITION CONTAINING MICROBIAL ZEAXANTHIN AND PREPARATION THEREOF - The present invention relates to a composition for prevention and/or treatment of human skin alteration or disease comprising an extract of marine bacteria selected from Flavobacteriaceae, wherein the extract contains an effective amount of zeaxanthin. The present invention also relates to a method for preparing the above composition, comprising: (a) culturing marine bacteria selected from Flavobacteriaceae, more specifically, from | 04-19-2012 |
20120108673 | PROCESS FOR ISOLATION OF LUTEIN AND ZEAXANTHIN CRYSTALS FROM PLANT SOURCES - The present invention provides for a process for isolation of carotenoids crystals comprising drying a plant part to obtain a meal and extracting the meal with alcohol at a temperature in the range of about 50° C. to 75° C. to obtain oleoresin. The oleoresin is enriched with alcohol at a temperature in the range of about 25° C. ° C. to 50° C. and hydrolyzed with alcoholic alkali at a temperature in the range of about 70° C. to 80° C. to obtain reaction mixture. The carotenoids crystals are precipitated from the reaction mixture by adding hot water followed by filtering, washing and drying the carotenoids crystals. The present invention also relates to carotenoids crystals comprising lutein and zeaxanthin in the ratios of about 10:1 or 5:1 or 1:1 obtained by a process which comprises mixing an oleoresin rich in lutein and an oleoresin rich in zeaxanthin separately in a ratios ranging from about 80:20 (w/w) to 90:10 (w/w) or about 70:30 (w/w) to 30:70 (w/w) or about 10:90 (w/w) to 20:80 (w/w) and homogenized to obtain a mixed oleoresin. The mixed oleoresin is then hydrolyzed with an alcoholic alkali at a temperature of about 70° C. to 80° C. to obtain a reaction mixture. The carotenoids crystals are precipitated by adding hot water to the reaction mixture to form a precipitate. Carotenoids crystals having lutein and zeaxanthin in a weight ratio of about 10:1 or 5:1 or 1:1 respectively are obtained by filtering, washing and drying the precipitate. | 05-03-2012 |
20120157547 | COMPOSITIONS AND APPLICATIONS OF CAROTENOIDS OF IMPROVED ABSORPTION AND BIOAVAILABILITY - Micro micellar form of carotenoids or xanthophylls, which show improved absorption and biovailability by living organisms, providing higher levels of carotenoids in the blood stream, and consequently are deposited at the target tissues at a faster rate, and more efficiently than crystalline carotenoids, which does not contain any crystal forms of carotenoids, and which are obtained as micro micelles after melting Lutein diacetate or Lutein dipropionate in their natural original lipid vegetable matrix, in the presence of lipids, phospholipids, fatty acids, emulsifiers and moisture, and are ingested in a dosage between 2 to 50 mg, to provide an absorption of the carotenoid solubilizate which is at least 20% above than that of crystalline carotenoids, and provides a macular pigment deposit which exceeds at least 10% of Macular Pigment Optical Density, than the deposition obtained by ingesting crystalline Lutein. Thus preventing tissue degeneration, UV light damage to skin and the retina, and in general to act as more effective and efficient antioxidants than when administered in crystalline form. | 06-21-2012 |
20120157548 | USE OF CYCLOALIPHATIC DIOLS AS BIOCIDES - Use of diols with a cycloaliphatic group as biocide. | 06-21-2012 |
20120157549 | METHODS OF PREVENTING, TREATING AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION - Disclosed are methods of preventing, treating, or diagnosing in a subject a disorder in protein folding or aggregation, or amyloid formation, deposition, accumulation, or persistence consisting of administering to said subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof. | 06-21-2012 |
20120232162 | USE OF LUTEIN CONTAINING COMPOSITIONS TO IMPROVE CERTAIN ASPECTS OF MEMORY - This invention relates to a method of enhancing an aspect of memory in a healthy individual, wherein the aspect of memory is selected from the group consisting of: associative memory, spatial memory and memory under stress comprising: administering a composition consisting of: a) an effective amount of either lutein or the combination of lutein and zeaxanthin; and b) an appropriate carrier; and observing the enhanced associative memory, spatial memory or memory under stress. | 09-13-2012 |
20120270953 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFECTION OR INFECTIOUS COLONIZATION OF THE EYELID, OCULAR SURFACE, SKIN OR EAR - The instant invention provides methods and compositions for the treatment of infection or infectious colonization of the eyelid and/or ocular surface for the treatment and prevention of ocular disorders and eyelid disorders. | 10-25-2012 |
20130005830 | SANDALWOOD OIL AND ITS USES - Provided herein are compositions of sandalwood oil and methods of making and using such compositions. | 01-03-2013 |
20130059918 | Throat irritation relief beverage - A composition beverage and method for relieving a symptom of a sore throat of a user. The composition comprises an aqueous base and an effective amount of a throat soreness relieving agent. The relieving agent may comprise between 0.001% w/v and 0.02% w/v of menthol. The beverage comprises a water base and including between 0.001% w/v and 0.02% w/v of a throat soreness relieving agent. The method comprises the administration of a safe and effective amount of a composition comprising an aqueous base and an effective amount of a throat soreness relieving agent. | 03-07-2013 |
20130072571 | EVAPORATIVE COOLING COMPOSITION - A liquid evaporative cooling composition has been discovered which is peculiarly effective in providing relief from heat-related discomfort. The composition utilizes a concentrate, dissolved in water, which preferably consists essentially of (a) about forty-three percent by weight of an alcohol; (b) about twelve percent by weight of a surfactant; (c) about four percent by weight of an aromatic oil; (d) about one percent by weight of a cooling agent; and (e) about forty percent by weight of water. | 03-21-2013 |
20130150456 | ANTIBACTERIAL AGENT AND DISINFECTING METHOD - To provide an antibacterial agent effective against gram-positive bacteria, particularly an antibacterial agent that is safe even when added to foods and the like, and a disinfecting method. | 06-13-2013 |
20130158127 | TEA TREE OIL DERIVATIVES - Some embodiments comprise tea tree oil derivatives, and compositions and uses of same, which have decreased cytotoxic and irritating characteristics. | 06-20-2013 |
20130184354 | Silicone and Hylauronic Acid (HLA) Delivery Systems for Products by Sustainable Processes for Medical Uses Including Wound Management - Topically absorbable compositions with bioactive or bioavailable cannabis-derived cannabinoids known to be effective for CB1 or CB2 modulation, and a plurality of indications for patients in need, and methods for producing composition, without detectable or biologically active levels of THC. Method uses a heat cycle process to combine cannabinoids with flax seed oil and at least one triglyceride, to produce an extract. The extract can include non-psychoactive agents, namely, CBD and accordingly does not deleteriously impact federal legal schemes or bone fide drug-testing regimes. | 07-18-2013 |
20130253070 | COMBINATION OF CAROTENOIDS AND EPI-LUTEIN - The invention describes the preparation and use of carotenoid and epi-lutein compositions to treat various ocular diseases. | 09-26-2013 |
20130281545 | Protection Against Sunburn And Skin Problems With Topical And Orally-Ingested Dosages Of Zeaxanthin - A carotenoid substance called zeaxanthin, when ingested orally at suitable dosages such as 30 to 100 mg/day for a span of 1 to 2 weeks, can provide effective protection against sunburns, and can give skin a darker tint that emulates a healthy suntan. In tests involving adults, it was found that zeaxanthin dosages of 30 to about 80 mg per day were sufficient to induce: (i) a mild but noticeable tinting, shading, or darkening of skin color, comparable to a mild suntan; (ii) a substantial increase in the person's ability to withstand elevated levels of sun or UV exposure without any subsequent pain or discomfort, and without the subsequent peeling and flaking that characterizes sunburns; and, (iii) an increased ability of reddened and sunburned skin to convert into intact skin that looks browned and healthily tanned. By reducing the amount of exposure to sunlight (or tanning lights) that are required to achieve a desired level of tanning, zeaxanthin can reduce the risks of skin cancer, premature aging or wrinkling, and similar skin problems. Since zeaxanthin also has retina-protecting properties and reduces the risk of a disease called macular degeneration, oral ingestion of these dosages of a zeaxanthin to enhance a tanned appearance and/or to protect against sun damage is believed to pose no health risks, and can offer several benefits due to the anti-oxidant and other activities of zeaxanthin. | 10-24-2013 |
20130296442 | LUTEIN/ZEAXANTHIN FOR GLARE PROTECTION - The invention relates to the improvement of visual performance, particularly of visual performance in the darkness, by administration of a colorant that is capable of being incorporated into eye tissue and/or causing yellowing of eye tissue, especially carotenoids, such as lutein and zeaxanthin. | 11-07-2013 |
20130331459 | A-Ring Modified 19-Nor-Vitamin D Analogs and Their Uses - Disclosed are 19-nor-vitamin D compounds, and specifically seco-A-2,19-dinor-1,25-dihydroxyvitamin D | 12-12-2013 |
20140031434 | Use of Patchouli Alcohol in Preparation of Drug Against Helicobacter Pylori - The present invention relates to a use of patchouli alcohol in the preparation of a drug against | 01-30-2014 |
20140073701 | METHODS OF PREVENTING, TREATING AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION - Disclosed are methods of preventing, treating, or diagnosing in a subject a disorder in protein folding or aggregation, or amyloid formation, deposition, accumulation, or persistence consisting of administering to said subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof. | 03-13-2014 |
20140073702 | LUPEOL ANTI-TUMOR AGENT AND USES THEREOF - Methods for the prevention, treatment and/or alleviation of skin disorders and skin cancers, and for the prevention, treatment and/or alleviation of prostate cancer and pancreatic cancer by administering a Lupeol-derived anti-tumor compound are disclosed. Pharmaceutical and nutraceutical compositions containing Lupeol-derived anti-tumor compounds are also disclosed. | 03-13-2014 |
20140080919 | FOAMING ALCOHOL COMPOSITIONS WITH SELECTED DIMETHICONE SURFACTANTS - Foaming alcohol compositions with selected dimethicone surfactants are disclosed. The dimethicone surfactants are PEG-8 to PEG-12 linear dimethicone surfactants and in particular PEG-10 linear dimethicone surfactant. The compositions are useful as antimicrobial products and in particular handcare or skincare products. | 03-20-2014 |
20140135403 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASES - The present invention relates to methods of treating ocular diseases in a subject by administering to the subject a therapeutically effective amount of one or more cyclohexanehexyl derivatives, or salts thereof, or a medicament comprising a cyclohexanehexol derivative and a pharmaceutically acceptable carrier. More specifically, the invention provides a medicament comprising at least one cyclohexanehexyl derivative of formula (III) or (IV) useful in preventing or treating ocular diseases, by modulating the folding, oligomerization or aggregation of amyloid β in ocular cells. Methods of administration of these medicaments include systemic, transpleural, oral, intravenously, intraarterial, intramuscular, topical, via inhalation, transdermal, subcutaneous, intraperitoneal, gastrointestinal, and directly to the eye or tissues surrounding the eyes. Formulae (III), (IV). | 05-15-2014 |
20140135404 | SESQUITERPENES FOR ANTIFUNGAL APPLICATIONS - Bicyclic sesquiterpene compounds exhibiting antifungal characteristics are formulated into antifungal compositions for use in the treatment of fungal infections in humans, animals, and plants. Particularly, sesquiterpene alcohols derived from drimane have been discovered to possess broad-spectrum antifungal characteristics. Exemplary antifungal sesquiterpene compounds include albicanol and drimenol, which have been shown effective against a number of pathogenic fungi. | 05-15-2014 |
20140187647 | METHODS OF IDENTIFYING SUBJECTS IN NEED OF TREATMENT AND METHODS OF IMPROVING VISUAL PERFORMANCE - Systems and methods may be provided for improving the visual performance of a human subject without the need to test the macular pigment concentration in the eye or eyes of the subject. The method may include identifying a subject likely to have an atypical ‘central dip’ macular pigment distribution; and administering an amount of a macular pigment-containing composition sufficient to improve the visual performance of the subject. Identifying a human subject, more likely than a subject selected at random from the general population, to have an atypical ‘central’ dip macular pigment distribution may include measuring at least one cognitive function of the subject; comparing the measured cognitive function with a pre-determined threshold; and, if the measured cognitive function is below the threshold, declaring the subject as being more likely to have an atypical ‘central dip’ macular pigment profile. | 07-03-2014 |
20140187648 | Identifying Subjects in Need of Treatment - A method of identifying a human subject, more likely than a subject selected at random from the general population, to have one or more of the following: (i) a low macular pigment concentration in the eye or eyes; (ii) a low visual performance, or (iii) an atypical “central dip” macular pigment distribution; the method comprising the steps of: measuring at least one cognitive function of the subject; comparing the measured cognitive function with a pre-determined threshold; and, if the measured cognitive function is below the threshold, declaring the subject as being more likely to have one or more of low macular pigment concentration in the eye or eyes, low visual performance or an atypical ‘central dip’ macular pigment profile. | 07-03-2014 |
20140243422 | METHODS OF TREATING BEHAVIORAL AND PSYCHIATRIC DISORDERS - The invention relates to the treatment of disorders associated with elevated myo-inositol levels in brain, in particular behavioural and neuropsychiatry disorders such as dementia, mild Alzheimer's disease, mild cognitive impairment or bipolar disorder by administering an effective amount of scyllo-inositol to a subject. | 08-28-2014 |
20140256829 | Method for Producing Lutein from Tobacco - A method for producing lutein from one or more plants of genus | 09-11-2014 |
20140256830 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE - Provided herein are methods and compositions comprising resorcinol derivatives for the use of treating, regulating or preventing a skin condition characterized by oxidative stress or a degenerative process. Methods of preventing, lightening or reducing the appearance of visible discontinuities of the skin resulting from skin pigmentation, skin aging, or other disorders are also disclosed. | 09-11-2014 |
20140296351 | PHARMACEUTICAL FORMULATION - The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant. | 10-02-2014 |
20140323584 | MICROBIAL COMPOSITION - A synergistic microbicidal composition comprising: (a) at least one microbicide selected from the group consisting of a monosubstituted phenol and an isopropyl methyl phenol; and (b) at least one microbicide selected from the group consisting of substituted cyclohexyl propyl-1,3-diols, propen-2yl-methyl cyclohexanols and menthadiene alcohols. | 10-30-2014 |
20140323585 | MICROBIAL COMPOSITION - A synergistic microbicidal composition containing synergistic combinations of a phenolic compound selected the class consisting of chlorinated phenols, monosubstituted phenols, fused bicyclic phenols, isopropyl methyl catechols and monosubstituted catechols and an antimicrobial alcohol selected from the class consisting of propen- | 10-30-2014 |
20140350121 | ANTIMICROBIAL COMPOSITION - The present invention relates to an antimicrobial composition and a method for disinfection involving the antimicrobial composition. It particularly relates to an antimicrobial composition for personal cleaning, oral care or hard surface cleaning applications. It was found that compositions comprising one or more monosubstituted phenols, terpineol and a carrier provide synergistic antimicrobial action. In a preferred aspect the composition also comprises 1 to 80%-wt of one or more surfactants. | 11-27-2014 |
20140350122 | ANTIMICROBIAL COMPOSITION - The present invention relates to an antimicrobial composition and a method for disinfection involving the antimicrobial composition. It particularly relates to an antimicrobial composition for personal cleaning, oral care or hard surface cleaning applications. It was found that compositions comprising thymol, selected propen-2-yl-methyl-cyclohexanols, and a carrier provide synergistic antimicrobial action. In a preferred aspect the composition also comprises 1 to 80%-wt of one or more surfactants. | 11-27-2014 |
20150018428 | LUTEIN/ZEAXANTHIN FOR GLARE PROTECTION - The invention relates to the improvement of visual performance, particularly of visual performance in the darkness, by administration of a colorant that is capable of being incorporated into eye tissue and/or causing yellowing of eye tissue, especially carotenoids, such as lutein and zeaxanthin. | 01-15-2015 |
20150031776 | METHOD OF PREVENTING, TREATING AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION - Disclosed are methods of preventing, treating, or diagnosing in a subject a disorder in protein folding or aggregation, or amyloid formation, deposition, accumulation, or persistence consisting of administering to said subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof. | 01-29-2015 |
20150126614 | Hyaluronic Acid Production Promoter And Melanin Production Inhibitor - A hyaluronic acid production promoter and a melanin synthesis inhibitor include soybean saponin as an active ingredient. The soybean saponin can be a soybean saponin aglycone, such as soyasapogenol A and/or soyasapogenol B. The hyaluronic acid production promoter and melanin synthesis inhibitor can be administered transdermally or orally. | 05-07-2015 |
20150141523 | COMPOUNDS FOR USE IN THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASE - A compound of the absolute stereochemical formula | 05-21-2015 |
20150306044 | MILD ANTIBACTERIAL CLEANSING COMPOSITIONS - Disclosed is a cleansing composition comprising: (i) a non-soap surfactant which is an alkyi glycinate, alkyi carboxy glycinate, sarcosinate, glutamate or a mixture thereof; and, (ii) one or more antimicrobial agent, wherein pH of said composition is at least 8.5 and zein number of said composition is in the range of 10 to 65 and wherein soap content of said composition is not greater than 5 wt %. The formulation is highly alkaline, yet gives mild antibacterial cleansing action. | 10-29-2015 |
20150328158 | HYDROPHILIC MATRIX BEADLET COMPOSITIONS WITH ENHANCED BIOAVAILABILITY - The instant invention provides hydrophilic matrix beadlet compositions that include at least one fat soluble nutrient and an effective amount of cellulose polymer with low viscosity. The invention also provides a process for the preparation of the hydrophilic matrix composition by employing a fluid bed system or extrusion spheronization technique. This hydrophilic matrix beadlet composition is comprised of at least 5% to about 25% carotenoid wherein free lutein is present in combination with zeaxanthin. The free flowing nature of the composition allows it to be compressed into tablets or to be filled into two piece capsules or blended as a dry premix for beverage applications. These hydrophilic matrix compositions exhibit desired dissolution characteristics and at least 1.6 times more bioavailability as compared with marketed reference formulations containing modified starch, thus making it advantageous for nutraceutical applications. | 11-19-2015 |
20150328170 | SYNERGISTIC PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF LUNG CANCER - The present invention relates to a synergistic pharmaceutical composition comprising Compound C2 (Neo-isopulegol), C3 (Iso-pulegol) and C4 (Citronellol) derived from herbal seed extract of | 11-19-2015 |
20150342902 | STABLE CANNABINOID FORMULATIONS - The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use. | 12-03-2015 |
20150361040 | BETA-CRYPTOXANTHIN FROM PLANT SOURCE AND A PROCESS FOR ITS PREPARATION - The present invention provides beta-cryptoxanthin crystals from plant source and a process for its preparation. The present invention particularly relates to a process for the preparation of high purity beta-cryptoxanthin crystals comprising at least about 10% by weight total xanthophylls, of which at least about 75% by weight is trans-beta-cryptoxanthin and the remaining including beta-carotene, and trace amounts of trans-capsanthin and other carotenoids derived from the plant source, including | 12-17-2015 |
20160000729 | NEURONAL CIRCUIT-DEPENDENT NEUROPROTECTION BY INTERACTION BETWEEN NICOTINIC RECEPTORS - A method of inhibiting excitotoxicity by indirectly activating α4β2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed Inhibitors of α7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate α4β2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis. | 01-07-2016 |
20160008296 | Zeaxanthin Formulations With Additional Ocular-Active Nutrients, For Protecting Eye Health And Treating Eye Disorders | 01-14-2016 |
20160053227 | AGENT FOR INDUCING DIFFERENTIATION OF WHITE ADIPOCYTES INTO BROWN-LIKE ADIPOCYTES - This invention relates to an agent for inducing differentiation of white adipocytes into brown-like adipocytes comprising a compound which is a cyclization reaction product of a hydroxystilbene and which is represented by Formula (1): (wherein each of R | 02-25-2016 |
20160101063 | CANNABIDIOL FOR THE PREVENTION AND TREATMENT OF GRAFT-VERSUS-HOST DISEASE - The invention provides methods for preventing, ameliorating and treating the acute and chronic forms of graft-versus-host disease (GVHD) by using Cannabidiol compositions. | 04-14-2016 |
20160106660 | USE OF AN ESSENTIAL OIL OF ORIGANUM MAJORANA, AS AN AGENT FOR TREATING AND/OR PREVENTING GREASY SKIN AND/OR THE ASSOCIATED AESTHETIC SKIN DEFECTS - The present invention relates to the cosmetic use, as an agent for treating greasy skin and/or preventing greasy or greasy-prone skin and/or the associated aesthetic skin defects, of an essential oil of | 04-21-2016 |
20160151301 | Compositions and methods for treating alzheimer`s disease and related disorders and promoting a healthy nervous system | 06-02-2016 |
20160166514 | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | 06-16-2016 |